

Bölüm 7

BPH'DA LAZER ÇEŞİTLERİ VE KULLANIM ALANLARI

YAZAR: Güçlü GÜRLEN

1. Giriş
2. Neodymium: yttrium-aluminium-garnet (Nd:YAG)
3. Nd: YAG Lazerin BPH' da Kullanım Yerleri:
 - A. Transurethral ultrasound-guided laser-induced prostatectomy TULIP (ultrason eşliğinde transüretal lazer prostatektomi)
 - B. Visual laser ablation of the prostate (VLAP) (görsel prostat lazer ablasyonu)
 - C. Contact Laser Ablation of the Prostate (CLAP) (kontak lazer prostat ablasyonu)
 - D. Interstitial Laser Coagulation (ILC) (interstisyal lazer koagülasyon)
4. Potassium-titanyl-phosphate:yttrium-aluminium-garnet (KTP: YAG) lazer
5. Lityum Triborat (LBO) lazer
6. Holmium: yttrium-aluminium-garnet (Ho: YAG) lazer
 - A. "Holmium laser ablation of the prostate" HoLAP (holmium lazer ile prostat ablasyonu)
 - B. Holmium laser resection of prostate HoLRP (holmium lazer ile prostat rezeksiyonu)
7. Diode lazer
8. Thulium (Tm) ittrium aliminium-garnet lazer

Kaynaklar

1. Luis Miguel Clemente Ramos. high power 980 nm diode laser preliminary results in the treatment of benign prostatic hyperplasia. Arch. Esp. Urol. 2009;62:125-30.
2. Abdel-Khalek M, El-Hammady S, Ibrahim el H: A 4-year follow-up of a randomized prospective study comparing transurethral electrovaporization of the prostate with neodymium: YAG laser therapy for treating benign prostatic hyperplasia. BJU international 2003, 91(9):801-805.
3. Keoghane SR, Lawrence KC, Gray AM, Doll HA, Hancock AM, Turner K, Sullivan ME, Dyar O, Cranston D: A doubleblind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow-up. BJU international 2000, 85(1):74-78
4. Reich O, Bachmann A, Siebels M, Hofstetter A, Stief CG, Sulser T: High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. The Journal of urology 2005, 173(1):158-160
5. Pawan V, Anup K, Niraj K, Biswajit N, Punita R, Rajendra A, Nayan M: Safety and efficacy of photoselective vaporization of prostate in patients receiving anticoagulants Pawan V., A. Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2013, 65(3):189-195.
6. Wosnitzer MS, Rutman MP. KTP/LBO laser vaporization of the prostate. Urol Clin North Am. 2009;36:471-483.
7. Heinrich E, Wendt-Nordahl G, Honeck P, et al. 120 W lithium triborate laser for photoselective vaporization of the prostate: comparison with 80 W potassium-titanyl-phosphate laser in an ex-vivo model. J Endourol. 2010;24:75-79.
8. Cornford PA, Biyani CS and Powell CS: Transurethral incision of the prostate using the Holmium: YAG laser: A catheter less procedure. J Urol 1998; 159:1229-1231.
9. Kabalin JN. Holmium:YAG laser prostatectomy: Canine feasibility study. Laser Surg Med 1996; 18:221-224.
10. Gravas S, Bachmann A, Reich O, Roehrborn CG, Gilling PJ, De La Rosette J. Critical review of lasers in benign prostatic hyperplasia (BPH) BJU Int. 2011;107:1030-1043.
11. Sener TE, Butticiè S, Macchione L, Netsch C, Tanidir Y, Dragos L, vd. Thulium laser vaporesction of the prostate: can we operate without interrupting oral antiplatelet/anticoagulant therapy? Investig Clin Urol 2017;58(3):192-9
12. McCullough DL, Roth RA, Babayan RK ve ark.: Transurethral ultrasound-guided laser-induced prostatectomy: National Human Cooperative Study results. J Urol 1993; 150:1607-1611.
13. Kabalin JN: Laser prostatectomy is a safer, beter operation than electrovaporization of the prostate. Urology 1997; 49:160- 65.
14. Sengor F, Gurdal M, Tekin A ve ark. Neodymium: YAG Visual Laser Ablation of the Prostate: 7 Years Of Experience With 230 Patients. J Urol. 2002; 167(1): 184-187.
15. Keoghane SR, Sullivan ME, Doll HA ve ark. Five year data from the Oxford Laser Prostatectomy Trial. BJU Int 2000; 86:227-228.
16. Bryan NP, Klingler HC, Cutinha PE ve ark. Analysis of a randomised trial betwe-

- en visual laser ablation and contact laser ablation of prostate. Eur Urol 1998; 33:4.
17. Laguna MP, Alivizatos G and de-la Rosetta JJMCH. Interstitial laser coagulation in the treatment of benign prostatic hyperplasia: Is it to be recommended? J Endourol 2003; 17:595- 600.